About Psoriasis

Together, we can positively impact patients living with psoriasis

Psoriasis (Ps) is a dermatologic disease that’s more than what you may see on the surface. The disease can have a significant impact on both patients’ lives and their emotional well-being. Explore real patient stories as they live with their condition.

Start impacting patients

Disease Education

The better we understand Ps, the better prepared we will all be in helping patients gain control over this condition.

Real-world achievement of the National Psoriasis Foundation’s treat-to-target goals in the US1

69

69.3% was the overall proportion of patients achieving BSA ≤3% after at least 3 months of treatment (48.8%, 85.4%)

Real-world achievement of the National Psoriasis Foundation’s treat-to-target goals in the US

43

43.4% was the overall proportion of patients achieving BSA ≤1% after at least 3 months of treatment (5.6%, 80.9%)

Real-world achievement of the National Psoriasis Foundation’s treat-to-target goals in the US

≥80–100%

≥60–<80%

≥40–<60%

≥20–<40%

>0–<20%

0%

No Data

Less than half of patients are reaching target BSA ≤1%.

These results were consistent across multiple sensitivity analyses. This analysis used data from OM1 Inc.’s Psoriasis PremiOM™ Dataset, including EMR systems, laboratory results, e-prescribing data, clinical observations, certain PROs and medical and pharmacy claims data. Patients with Ps ≥18 years across the US who initiated an advanced therapy (TNF, IL-12/23, IL-17, IL-23 or PDE-4 inhibitors) between January 1, 2021, to September 30, 2022, and had at least 1 BSA measure ≥90 days after treatment initiation were included in the analysis. Data from 6,395 patients were included in this analysis. BSA=body surface area; EMR=electronic medical records; IL=Interleukin; PDE=phosphodiesterase; TNF=tumor necrosis factor.

Re-Categorization of Psoriasis Severity2

The 2020 International Psoriasis Council (IPC) Consensus statement describes two categories of psoriasis severity:

1. Candidates for topical therapy

2. Candidates for systemic therapy*

Psoriasis patients classified as candidates for systemic therapy meet at least 1 of the following criteria:

BSA >10% BSA >10%
Disease involving special areas† Disease involving special areas†
Failure of topical therapy Failure of topical therapy

*Systemic therapies include both biologic and non-biologic treatments such as phototherapy and older systemic agents. †’Special areas’ refers to psoriasis affecting more impactful sites such as the face, palms, soles, genitalia, scalp, or nails.

Explore our videos below to learn more about psoriasis.

Watch the videos

References: 1. Armstrong AW, Amin AZ, Gondo G, et al. The “Pstate” of the union: real-world achievement of NPF treat to target goals in psoriasis in the United States. Poster presented at: The National Psoriasis Foundation Research Symposium; October 7, 2023; Washington, DC. 2. Strober B, Ryan C, van de Kerkhof P, et al. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. J Am Acad Dermatol. 2020;82(1):117-122. doi:10.1016/j.jaad.2019.08.026

Treatment Considerations

You and your patients have many treatment options—such as phototherapy and topical/systemic therapies—to consider for Ps.
Take a look at information that may help with your treatment considerations.

Who Might Benefit
From a Biologic?
2:36
Chapter 1: Unpacking Severity of Disease
2:06
Chapter 2: Special Areas, Special Care: Treating Psoriasis Beyond the Surface
3:56
Chapter 3: Comorbidities and Patient Impact
2:27
Chapter 4: Elevating the Standard of Care: Patient Perceptions
Bio-eligible: 

What Next?
3:59
Chapter 1: Navigating the Landscape of Biologic Therapies for Psoriasis
2:23
Chapter 2: Finding Office Efficiencies in Treatment with Biologics
2:52
Chapter 3: Practical Considerations for Initiation and Management of Biologic Therapy
2:25
Chapter 4: Additional Resources
Treatment Considerations – Shared Decision-making
1:42
Chapter 1: Psoriasis Is a Systemic Disease
1:49
Chapter 2: Risks of Systemic Therapies for Psoriasis
1:26
Chapter 3: Safety Considerations of Biologic Therapy
1:01
Chapter 4: Assessing a Patient’s Current Therapy for Safety/Tolerability
2:05
Chapter 5: Considerations for Starting a Biologic Therapy
The Dermatologist’s 

Guide
4:18
Chapter 1: Bridging the Gap of Treating to Clear and Patient Impact
3:18
Chapter 2: Perspectives on Approaching the Patient Conversation
2:43
Chapter 3: Approaches to Meeting Your Patient’s Treatment Expectations
1:07
Chapter 4: Simplifying the Treatment Switch Conversation
1:51
Chapter 5: Raising Treatment Expectations in Psoriasis
Rethinking 

Psoriasis
4:54
Learn from a leading dermatologic expert on how the industry is looking to elevate the treatment outlook for Ps.
Challenging 

“Good Enough”
4:19
Gain an understanding of how treatment goals to help patients manage Ps are evolving.
2:36
Chapter 1: Unpacking Severity of Disease
2:06
Chapter 2: Special Areas, Special Care: Treating Psoriasis Beyond the Surface
3:56
Chapter 3: Comorbidities and Patient Impact
2:27
Chapter 4: Elevating the Standard of Care: Patient Perceptions

Each shade of skin deserves care

Watch and learn from leading clinical experts on how we can improve
dermatologic care for patients of color living with Ps.

Watch video